Biotech executives are panicking over empty chairs. Following the resignation of FDA Commissioner Marty Makary, the mainstream financial press is flooded with hand-wringing commentary about a "leadership void" and "regulatory uncertainty." Analysts are warning that having temporary, acting directors across three major pillars of drug regulation will paralyze drug development timelines and scare away life science venture capital.
This panic is entirely wrongheaded. It mistakes bureaucratic musical chairs for operational failure. Discover more on a similar issue: this related article.
I have spent twenty years navigating the regulatory pathways of the biotechnology industry, watching companies burn tens of millions of dollars while waiting on executive-level sign-offs. The reality inside the labs and review rooms is far different from the narrative on Wall Street. A revolving door at the top of the Food and Drug Administration is not a systemic vulnerability. It is a feature that strips away the cult of personality from drug approvals, forcing the agency to rely on its only asset that actually matters: its standardized, data-driven framework.
The Fallacy of Institutional Memory
The prevailing lament among biotech watchers is the loss of "institutional memory." Commentators point to the departures of veteran regulators like Peter Marks, Richard Pazdur, and Rachael Anatol as if the agency’s scientific capability walked out the door with them. Additional reporting by MarketWatch delves into comparable views on the subject.
This view fundamentally misunderstands how modern drug evaluation works. Institutional memory in a regulatory body is frequently a euphemism for entrenched bias and predictable stagnation. When a single director sits atop a review center for a decade, drug development pipelines morph to satisfy the specific scientific quirks and personal philosophies of that individual.
Consider the recent whiplash surrounding cell and gene therapies. Under historical leadership, the Center for Biologics Evaluation and Research relied heavily on subjective "regulatory flexibility." While this allowed for a few high-profile breakthrough approvals, it created an ad-hoc system where small biotech firms had to guess what kind of surrogate endpoints would satisfy a specific director's mood on any given Tuesday.
When Vinay Prasad stepped into the biologics oversight role and enforced a rigid, conservative interpretation of clinical trial data—clashing publicly with Sarepta Therapeutics over its gene therapy Elevidys—the industry cried foul. But Prasad was simply exposing the core flaw of the old system: when regulation depends on the philosophy of one person, the entire industry is exposed to single-point-of-failure risk.
An agency run by career bureaucrats with permanent tenure becomes a political kingdom. An agency staffed by temporary, acting directors is forced to do something far more radical: follow its own written guidelines.
The Operational Mechanics of the Acting Director
To understand why the panic is overblown, look at the literal mechanics of the 210-day statutory limit placed on acting federal officials. Critics argue this short fuse prevents long-term strategic planning.
Good. The FDA does not need more grand, sweeping executive strategies. It needs to execute its core mandate of evaluating safety and efficacy metrics against clear legal thresholds.
When an acting director takes the helm of the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research, their incentives shift dramatically away from legacy-building. They are not trying to invent a new regulatory paradigm or write their name into the history books with a flashy new initiative. Instead, their primary goal is risk mitigation and operational continuity.
Under an acting director, the power structure shifts downward to the division heads and primary medical reviewers—the career scientists who actually read the thousands of pages of a New Drug Application. These reviewers do not care who is sitting in the commissioner's suite this month. They follow the established guidance documents, such as the 2026 CBER guidance agenda on individualized therapies for rare genetic disorders.
Imagine a scenario where a mid-sized pharmaceutical company is preparing a submission for a novel oncology drug. The executive team is terrified that a change in leadership means their submission will languish. In reality, the review team assigned to that file remains identical. The statistical protocols do not change. The advisory committee structures remain intact. The machine moves forward because it is designed to be indifferent to its leadership.
The Premium on Predictability vs. Innovation
Biotech trade groups routinely issue statements demanding "predictability and continuity" to enable industry innovation. This is a contradictory demand.
True innovation is messy, unpredictable, and inherently disruptive to established regulatory comfort zones. When the FDA leadership is static, the agency builds cozy relationships with mega-pharmaceutical companies that have the capital to build bespoke clinical trial designs tailored to old regulatory mindsets.
A disrupted, rotating leadership structure levels the playing field. It forces the regulatory process to become purely transactional. If your data meets the pre-specified endpoints, the drug moves forward. If your data relies on statistical gymnastics and political lobbying, it fails.
The downside to this decentralized approach is obvious: it eliminates the mechanism for exceptionalism. If you have a truly radical therapeutic modality that falls outside existing regulatory boxes, you no longer have a powerful, permanent champion at the top of the agency who can wave a magic wand and grant an accelerated approval based on gut feeling.
That is a loss for a handful of speculative moonshots, but it is a massive win for the broader market. It forces biotechnology companies to stop relying on regulatory arbitrage and start focusing on generating undeniable, hard clinical data.
Dismantling the Premier Premise of the Biotech Downturn
The financial markets love a scapegoat. It is easy for a venture capital firm to blame a down year or a failed fundraising round on "FDA leadership turmoil." It sounds sophisticated. It shifts the blame from poor asset selection to geopolitical forces beyond their control.
But look at the actual output of the agency during this period of supposed chaos. Even with five leadership changes at the head of CDER since early 2025, the agency managed to approve dozens of novel drug therapies last year. Programs like the priority review voucher system—designed to compress review times down to mere months for critical therapies—have continued to function and yield approvals without a permanent commissioner holding the rubber stamp.
The underlying premise of the current panic is fundamentally flawed:
- Flawed Premise: A vacant or temporary leadership slot at the FDA stops the approval pipeline.
- The Reality: The FDA is a self-executing regulatory machine. The pipelines are governed by statutory user-fee deadlines (PDUFA dates) that carry severe institutional penalties if missed. The clock ticks regardless of who is sitting in the corner office.
Stop asking who the next nominee will be. Stop trying to read the political tea leaves of the White House or Health and Human Services to predict the next shift in drug review philosophy.
The successful biotech play for the current era is to build clinical programs that are completely immune to regulatory mood swings. If your phase 3 trial requires a highly permissive, friendly regulator to squeeze through the finish line, your asset was already broken. Design trials with unambiguous, hard clinical endpoints that an acting director can approve with their eyes closed.
The system isn't broken because the leadership is gone. The system is finally working exactly as an objective, insulated regulatory machine should.
